Pedro Barata, MD, MSc, FACP, University Hospitals Seidman Cancer Center, and Christopher Wallis, MD, PhD, FRCSC, University of Toronto, discuss the interaction of age and benefit of treatment intensification in advanced prostate cancer, as well as the impact of SPOP gene alterations in men with metastatic prostate cancer.
Treatment Intensification, SPOP Gene Alterations in Advanced Prostate Cancer
By Pedro Barata, MD, Christopher Wallis, MD, PhD, FRCSC - Last Updated: January 30, 2024Related Posts
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.